

Improved survival shown in early-stage Hodgkin's Disease patients who receive radiation therapy

September 15 2014

Patients with stage I and II Hodgkin's Disease who receive consolidated radiation therapy (RT) have a higher 10-year survival rate of 84 percent, compared to 76 percent for patients who did not receive RT; and, the data also shows a decrease in utilization of RT, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 56th Annual Meeting.

Researchers evaluated clinical features and <u>survival outcomes</u> among 41,502 patients diagnosed with stage I and II Hodgkin's Disease from 1998 to 2011 from a prospectively collected database—the National Cancer Data Base (NCDB), which is comprised of cases from 1,500 sites and represents >75 percent of all cancers diagnosed in the U.S. The average patient age was 37 (range: 18 – 90), with a median follow-up of 7.5 years. The association between RT use, co-variables and outcome were assessed in a multivariate Cox proportional hazards model. Survival was estimated using the Kaplan-Meier method.

Multi-agent chemotherapy was administered to 96 percent (39,842) of the patients, and 49 percent (20,441) of patients received a median RT dose of 30.6 Gy. The 10-year overall survival of the entire group was 80.8 percent, with patients receiving RT having a statistically significant improved overall survival rate at 10 years, when compared to those not receiving RT (84.4 percent vs. 76.4 percent; p



Citation: Improved survival shown in early-stage Hodgkin's Disease patients who receive radiation therapy (2014, September 15) retrieved 4 February 2024 from https://medicalxpress.com/news/2014-09-survival-shown-early-stage-hodgkin-disease.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.